Work

Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML

Year: 2019

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-019-00786-4

Authors: Jae Yoon Jeon, Qiuhong Zhao, Daelynn R. Buelow, Mitch Phelps, Alison R. Walker, Alice S. Mims, Sumithira Vasu, Gregory Behbehani, James Blachly, William Blum, Rebecca B. Klisovic, John C. Byrd, Ramiro Garzon, Sharyn D. Baker, Bhavana Bhatnagar

Institutions: The Ohio State University, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Emory University, Winship Cancer Institute

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Awards: Targeted Therapy for Leukemia, G898439380, Cancer Center Support Grant (CCSG)

OpenAlex ID: W2946601400

FWCI: 3.32

Cites: 20

Cited by: 43

Related to: 10